<DOC>
	<DOCNO>NCT02493829</DOCNO>
	<brief_summary>The study open label , single arm , phase I study intend identify safety tolerability `` AML Cell Vaccine '' give eligible MDS RAEB-2 AML patient achieve best response complete remission partial remission follow first second course standard induction chemotherapy .</brief_summary>
	<brief_title>B7.1/IL-2 Leukaemia Cell Vaccine Non-Transplant AML RFUSIN2-AML2 ( NTX )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Key Diagnosis MDS RAEB2 primary ( de novo ) secondary AML define accord WHO classification either new diagnosis relapse . Patients optimal therapy CR1 would undergo allogeneic bone marrow transplantation , procedure either recommend ( e.g . due comorbidities ) available ( e.g . lack suitable donor ) . Key Patients MDS RAEB2 AML favourable prognostic profile ( good risk cytogenetics : ( 15 ; 17 ) ( q22 ; q12~21 ) , inv16 ( p13q22 ) /t ( 16 ; 16 ) ( p13 ; q22 ) , ( 8 ; 21 ) ( q22 ; q22 ) cytogenetically normal AML NPM1 mutation absence Flt3 ITD ) . Patients unsuitable standard induction chemotherapy . Patients previously undergone able undergo allogeneic transplantation . Patients previous current treatment form investigational immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>